Skip to content

Prospective Randomized Controlled Pilot Study of Gut Microbiome Modulation by Nigella Sativa Seed Oil and Thymoquinone Metabolism in Healthy Volunteers

Influence of Thymoquinone on the Human Gut Microbiome

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07450807
Enrollment
8
Registered
2026-03-05
Start date
2024-04-02
Completion date
2025-03-01
Last updated
2026-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Changes in Human Gut Microbiome in Healthy Adults

Keywords

Thymoquinone, Gut microbiome, Nigella sativa seed oil, Microbiota modulation, Thymoquionone metabolism

Brief summary

For many patients, the additive use of dietary supplements without side effects is motivating for therapy and enhances quality of life. The oil of the plant Nigella sativa (NS), a dietary supplement containing Thymoquinone (TQ) as its main active compound, exhibits hepatoprotective effects through antioxidative, antifibrotic, and anti-inflammatory properties, and also demonstrates anticancer and antiapoptotic activities. In vitro and in vivo studies have shown that TQ can also influence the gut microbiome. However, no clinical studies are currently available that describe the specific extent of TQ's influence on the human intestinal microbiome and its potential effects on the outcome after gastrointestinal surgery. The aim of the project is therefore to investigate changes in the human microbiome following the intake of Nigella sativa seed oil capsules containing TQ as the main active ingredient. The study will test the hypothesis that TQ, through its diverse mechanisms of action, modulates the composition of the microbiome and thereby exerts a positive effect on immune response and intestinal healing processes. In parallel, TQ metabolites in urine will be analyzed using Liquid Chromatography-Mass Spectrometry (LC-MS) to gain insights into the pharmacokinetic profile of the compound.

Interventions

DIETARY_SUPPLEMENTIntake of Thymoquinone (TQ) containing Nigella Sativa Seed Oil (NSSO) capsules

Intake of two Thymoquinone (TQ) containing Nigella Sativa Seed Oil (NSSO) capsules three times daily for 20 days and provision of fecal samples at five time points.

Sponsors

Aysun Tekbaş
Lead SponsorOTHER
Interdisciplinary Center of Clinical Research of the Medical Faculty Jena
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* no recent medication use * no history of gastrointestinal surgery * no pregnancy * no allergies to NSSO or its derivatives * healthy * 18 years and above

Exclusion criteria

* regular medication * history of gastrointestinal surgery * pregnancy * allergies to NSSO or its derivates * presence of chronic illness * below the age of 18 years

Design outcomes

Primary

MeasureTime frame
Changes in bacterial taxa in fecal samplesFrom enrollment to the end of treatment at 20 days.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 17, 2026